# Multi-Agent RA Expert Review Framework
## FDA API Enrichment Phase 1 & 2 Validation

**Review Date:** 2026-02-13
**Review Type:** Multi-perspective expert validation (stopgap for independent RA professional review)
**Scope:** CFR citations, guidance currency, standards intelligence, clinical data detection, disclaimers

---

## Review Objectives

This multi-agent review simulates independent expert validation by having specialized RA professionals from different medical device domains review the enrichment system. While this is a **stopgap measure** and not a substitute for actual RA professional review, it provides:

1. **Multi-perspective validation** - 6 experts across device types
2. **Domain-specific insights** - Each expert reviews their specialty area
3. **CFR/Guidance verification** - Cross-validation of regulatory citations
4. **Standards applicability** - Device-specific standards validation
5. **Quality assurance** - Identify issues before Phase 3/4 implementation

---

## Expert Team Composition

### 1. Cardiovascular Device RA Specialist
**Expertise:** Class II/III cardiovascular devices, 21 CFR 870, PMA/510(k) pathways
**Review Device:** DQY (cardiovascular catheter)
**Focus Areas:**
- CFR 21 Part 803 (MAUDE) applicability to cardiovascular devices
- Recall history interpretation for catheters
- IEC 60601-2-34 (medical electrical equipment - invasive blood pressure monitoring)
- Biocompatibility requirements (ISO 10993 series)
- Clinical data requirements for cardiovascular devices

### 2. Software/SaMD RA Specialist
**Expertise:** Software as a Medical Device, 21 CFR 820.30, cybersecurity, IEC 62304
**Review Device:** QKQ (digital pathology software)
**Focus Areas:**
- IEC 62304 (medical device software lifecycle) applicability
- IEC 62366 (usability engineering) for SaMD
- Cybersecurity guidance (2018) applicability
- Clinical data requirements for SaMD vs. hardware devices
- Special controls for software devices

### 3. Combination Product RA Specialist
**Expertise:** Drug-device combinations, 21 CFR 3.2(e), Class U, OTC labeling
**Review Device:** FRO (wound dressing with drug component)
**Focus Areas:**
- Combination product classification accuracy
- Special controls applicability assessment
- Class U vs. Class I/II/III distinctions
- OTC labeling requirements vs. prescription devices
- Drug component considerations in enrichment data

### 4. Orthopedic/Surgical Device RA Specialist
**Expertise:** Class II/III orthopedic implants, 21 CFR 888, biomaterials
**Review Device:** OVE (cervical spinal fusion device)
**Focus Areas:**
- ASTM F1717 (spinal implant constructs) applicability
- ISO 10993 biocompatibility for PEEK and titanium
- Material safety data requirements
- Long-term implant considerations
- Wear testing and fatigue testing standards

### 5. Electrosurgical/Energy-Based Device RA Specialist
**Expertise:** Class II electrosurgical devices, 21 CFR 878, IEC 60601-2-2
**Review Device:** GEI (electrosurgical unit)
**Focus Areas:**
- IEC 60601-1 (medical electrical equipment - general requirements)
- IEC 60601-2-2 (particular requirements for electrosurgical equipment)
- Electrical safety and performance testing
- EMC (electromagnetic compatibility) requirements
- Output power and tissue effect characterization

### 6. CFR/Guidance Compliance Auditor
**Expertise:** Regulatory citations, guidance document management, eCFR navigation
**Review Scope:** All devices (cross-cutting validation)
**Focus Areas:**
- 21 CFR 803 (MDR) - verify URL, scope, applicability
- 21 CFR 7 (Recalls) - verify URL, enforcement policy accuracy
- 21 CFR 807 (510(k)) - verify URL, premarket notification scope
- FDA Guidance currency check (2016 MDR, 2019 Recalls, 2014 SE)
- Superseded guidance identification
- eCFR vs. GPO accuracy

---

## Review Data Sources

### Test Devices (from batch testing)
1. **DQY** (Cardiovascular) - Product code DQY, 2024 clearances
2. **QKQ** (Digital Pathology) - Product code QKQ, SaMD, 2024 clearances
3. **FRO** (Combination Product) - Product code FRO, wound dressing + drug
4. **OVE** (Orthopedic) - Product code OVE, cervical fusion device
5. **GEI** (Electrosurgical) - Product code GEI, electrosurgical unit

### Enrichment Data Files (from integration)
- `510k_download.csv` - Enriched data with 29 columns
- `quality_report.md` - Phase 1 quality scoring
- `regulatory_context.md` - CFR citations and guidance references
- `intelligence_report.md` - Phase 2 clinical/standards analysis
- `enrichment_metadata.json` - Provenance tracking

### Reference Documents
- `lib/fda_enrichment.py` - Production enrichment code
- `lib/disclaimers.py` - Disclaimer generation
- `CFR_VERIFICATION_WORKSHEET.md` - CFR citation verification template
- `GUIDANCE_VERIFICATION_WORKSHEET.md` - Guidance currency template

---

## Review Criteria

### 1. CFR Citation Accuracy (Critical)
**Criteria:**
- [ ] CFR part numbers are correct (803, 7, 807)
- [ ] CFR URLs resolve to correct eCFR sections
- [ ] CFR scope descriptions are accurate
- [ ] CFR applicability logic is sound (when to cite each part)
- [ ] No missing critical CFR citations

**Validation Method:**
- Cross-reference with https://www.ecfr.gov/
- Check URL resolution and section content
- Verify applicability triggers in code

### 2. Guidance Document Currency (High Priority)
**Criteria:**
- [ ] Guidance titles are correct
- [ ] Publication dates are accurate (2016, 2019, 2014)
- [ ] No superseded guidance is referenced
- [ ] Guidance URLs resolve correctly
- [ ] Relevance descriptions are accurate

**Validation Method:**
- Search FDA guidance database: https://www.fda.gov/regulatory-information/search-fda-guidance-documents
- Check for "withdrawn" or "superseded" notices
- Verify publication dates

### 3. Standards Intelligence Accuracy (High Priority)
**Criteria:**
- [ ] ISO/IEC standards are correctly identified for device type
- [ ] Standard numbers are accurate (no typos)
- [ ] Standard applicability logic is appropriate
- [ ] No critical standards are missed
- [ ] Pattern matching doesn't create false positives

**Validation Method:**
- Compare against FDA Recognized Consensus Standards Database
- Check device-specific guidance for required standards
- Review predicate 510(k) summaries for standards precedent

### 4. Clinical Data Detection Logic (Medium Priority)
**Criteria:**
- [ ] "YES/PROBABLE/UNLIKELY/NO" classifications are reasonable
- [ ] Keywords detection is appropriate (not overly broad/narrow)
- [ ] Risk categorization (HIGH/MEDIUM/LOW) is sensible
- [ ] Special controls identification is accurate
- [ ] Disclaimers adequately communicate limitations

**Validation Method:**
- Manual review of decision descriptions
- Compare against actual 510(k) summary clinical sections
- Cross-reference with device-specific guidance on clinical data

### 5. Predicate Acceptability Logic (Medium Priority)
**Criteria:**
- [ ] Recall history weight is appropriate
- [ ] Age-based scoring (>10 years) is reasonable
- [ ] "NOT_RECOMMENDED" threshold is defensible
- [ ] Rationale text is clear and actionable
- [ ] Disclaimers communicate limitations adequately

**Validation Method:**
- Review FDA SE Guidance (2014) criteria
- Compare against FDA recall database data
- Assess logic against RA professional judgment

### 6. Quality Scoring Methodology (Low Priority)
**Criteria:**
- [ ] 0-100 scoring components are logical
- [ ] Point allocation is balanced (not overweighting any category)
- [ ] Score interpretation guidance is clear
- [ ] Disclaimers prevent misuse of scores
- [ ] Scoring adds value (not just noise)

**Validation Method:**
- Review score calculation logic in fda_enrichment.py
- Test edge cases (perfect device, incomplete device)
- Assess whether scores correlate with actual data quality

### 7. Disclaimer Adequacy (Critical)
**Criteria:**
- [ ] MAUDE scope limitation is prominently displayed
- [ ] Verification requirements are clear
- [ ] Regulatory disclaimer prevents misuse
- [ ] CFR citation disclaimers are appropriate
- [ ] Disclaimers appear in ALL output formats (CSV, HTML, MD, JSON)

**Validation Method:**
- Review all 6 output files for disclaimers
- Assess prominence and clarity
- Check for missing disclaimers

---

## Review Deliverables

### Individual Expert Reports
Each expert produces:
1. **Executive Summary** - 2-3 sentence overview of findings
2. **Critical Findings** - Issues that must be fixed before production use
3. **High Priority Findings** - Issues that should be addressed soon
4. **Medium Priority Findings** - Improvements to consider
5. **Low Priority Findings** - Nice-to-have enhancements
6. **Validation Confirmations** - What was verified as correct
7. **Recommendations** - Specific action items

### Consolidated Report
Final deliverable combining all expert input:
1. **Consensus Findings** - Issues flagged by 2+ experts
2. **Domain-Specific Findings** - Unique insights per specialty
3. **CFR/Guidance Validation Summary** - Pass/fail on each citation
4. **Standards Validation Summary** - Accuracy assessment per device type
5. **Overall Assessment** - Ready for production? Conditional approval? Not ready?
6. **Action Plan** - Prioritized list of required fixes

---

## Review Timeline

**Phase 1:** Individual Expert Reviews (parallel) - 30-45 minutes
- Each expert reviews their assigned device + cross-cutting areas
- Produces individual report

**Phase 2:** Cross-Validation - 15 minutes
- Experts compare findings on overlapping areas
- Identify consensus vs. dissenting opinions

**Phase 3:** Consolidated Report - 15-30 minutes
- Synthesize findings into actionable recommendations
- Prioritize issues
- Produce final assessment

**Total Estimated Time:** 1-1.5 hours

---

## Success Criteria

**Minimum Acceptable Outcome:**
- ✅ All CFR citations verified or corrected
- ✅ All guidance documents confirmed current (not superseded)
- ✅ Critical standards for each device type validated
- ✅ Disclaimers confirmed adequate and prominent

**Desired Outcome:**
- ✅ Consensus that enrichment logic is sound
- ✅ <5 critical findings requiring immediate fixes
- ✅ Clear action plan for any identified issues
- ✅ Confidence to proceed with Phase 3/4 planning

**Outstanding Outcome:**
- ✅ Zero critical findings
- ✅ Expert consensus on production readiness (with disclaimers)
- ✅ Valuable insights for Phase 3/4 feature design

---

## Limitations & Disclaimers

**This is a STOPGAP measure:**
- ⚠️ This is NOT a substitute for actual RA professional review
- ⚠️ AI agents may miss nuances that human experts would catch
- ⚠️ This provides validation confidence but not regulatory certification
- ⚠️ Before FDA submission use, independent RA professional review is still required

**Appropriate Use:**
- ✅ Internal validation before hiring RA professionals
- ✅ Identifying obvious errors before external review
- ✅ Building confidence in enrichment logic
- ✅ Prioritizing areas for future improvement

**Not Appropriate For:**
- ❌ Replacing qualified RA professional review
- ❌ Citing as "expert-validated" in FDA submissions
- ❌ Assuming 100% accuracy without verification

---

**END OF FRAMEWORK**
